Navigation Links
UT Southwestern scientist receives NIH Director's New Innovator Award
Date:10/1/2007

DALLAS Oct. 1, 2007 Dr. Tawanda Gumbo, an assistant professor of infectious diseases at UT Southwestern Medical Center, has been named one of the inaugural winners of the National Institutes of Health Directors New Innovator Award.

Dr. Gumbo is one of three Texas scientists and one of 29 nationwide to be named recipients of the award, which provides $1.5 million each over five years and is designed to recognize bold ideas from some of the nations most innovative new scientists. More than 2,100 applications were submitted.

The New Innovator Awards are given to early-career researchers who havent yet received a research project grant from the NIH. The awards are part of the NIH Roadmap for Medical Research, which promotes interdisciplinary and innovative research.

Dr. Gumbos research focuses on tuberculosis and extensively drug-resistant tuberculosis, a newly identified strain of TB that leaves patients virtually untreatable using existing anti-TB drugs. He has published numerous scientific papers on TB, AIDS and other infectious diseases.

About one-third of the worlds population is infected with mycobacterium tuberculosis, the bacterium that causes TB, and as many as 2 million people die of the disease each year. TB, which is the leading cause of death among people infected with HIV/AIDS, kills more people than any other disease caused by a single infectious agent, according to NIH data.

Dr. Beth Levine, professor of internal medicine and microbiology and chief of the division of infectious diseases at UT Southwestern, called the award a great honor for Dr. Gumbo.

The problem of drug resistance is emerging worldwide, Dr. Levine said. The idea that there might be a way to add a drug to prevent the resistance as well as to shorten and simplify therapy for all TB strains has major global health implications for treating this disease.

In his laboratory, Dr. Gumbo measures how antimicrobial drugs behave and how microbes react to those drug concentrations. The aim is to use such information from pharmacokinetics and pharmacodynamics to kill mycobacterium tuberculosis and keep more strains of TB from developing.

Dr. Gumbo said he was thrilled to receive the award.

It will allow me to actually do particular experiments that started with some techniques that I pioneered in the lab using the hollow fiber model of tuberculosis, the native of Zimbabwe said. The typical tuberculosis treatment takes many, many months; usually six months and nine months in some situations. Hopefully, well reduce it to weeks.

Over the five years of the award, Dr. Gumbo will develop a treatment regimen based on blocking the mechanisms that tuberculosis bacteria use to avoid being killed by antibiotics.

Dr. Gumbo, who joined the UT Southwestern faculty in 2006, graduated from the University of Zimbabwe Medical School in Harare, and completed his residency in internal medicine at Case Western Reserve University. He then completed a three-year fellowship to study infectious diseases at the Cleveland Clinic Foundation.

He spent a year doing research at the University of Zimbabwe before accepting a position in 2000 at Albany Medical College and the Ordway Research Institute in Albany, N.Y.

The other winners from Texas were Dr. Pedro Fernandez-Funez of the UT Medical Branch at Galveston and Dr. Kjersti Aagaard-Tillery of Baylor College of Medicine in Houston.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Scientists plan human cloning clinic in the United States
3. Scientists crack mechanism of Leptin-Obesity Hormone
4. Scientists use plant hormones to fight cancer
5. American scientists alter gene makeup of babies
6. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
7. Scientists found ancient Human Germ Killer
8. Scientists locate key hormone involved in appetite control
9. Scientists open the book of life
10. Electronic nose by Italian scientists
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... ... 21, 2017 , ... Northern California Medical Associates (NCMA) is ... multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, clinical ... this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, Ruth ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Lice Troopers, the lice removal company based in South Florida, has ... holiday season. , “It happens every year around this time,” says owner, Arie ... which is the head-to-head gateway that lice need to spread.” , As children return ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast ... VNDA ) today announced it will release results for the fourth ... closes. ... will host a conference call at 4:30 PM ET on Wednesday, ... and full year 2016 financial results and other corporate activities. To ...
(Date:1/19/2017)... LONDON , January 19, 2017 Incretin ... Sympathomimetics and Others The global anti-obesity drugs ... the first half of the forecast period and CAGR of 38.7% ... expected to grow at a CAGR of 32.8% from 2016 to ... million in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
Breaking Medicine Technology: